Continuous Intrasplenic Interleukin-2 Combined With Antigen-Specific Chemoimmunotherapy

Naito, Kazuyo; Pellis, Neal R.; Kahan, Barry D.

doi:10.1001/archsurg.1986.01400120065010

Arch Surg

1986

DOI: 10.1001/archsurg.1986.01400120065010

|View full text |Cite

Continuous Intrasplenic Interleukin-2 Combined With Antigen-Specific Chemoimmunotherapy

Kazuyo Naito¹,

Neal R. Pellis²,

Barry D. Kahan³

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1993

2014

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pilot testing of splenic artery infusion of IL-2 first took place in mouse models in the mid 1980's. 4 Subsequently in 1990, 20 patients with stage IV renal cell cancer, melanoma and lymphoma underwent a phase I clinical trial with low dose IL-2 continuously infused over 5 consecutive days at 3 weeks intervals for 2 -4 cycles via a splenic arterial catheter placed through the femoral artery. 5 Each patient received from 90,000 -240,000 IU/kg/day for a total dose of 450,000-1.2 millionIU/kg/cycle, much lower than the maximum dose of 8.4 million IU/kg/cycle with current systemic IL-2.…”

mentioning

confidence: 99%

Splenic artery infusion of IL-2 might allow treatment of melanoma and renal cell cancer with less side effects and greater efficacy

Alisky¹

2014

Int J Cancer Ther Oncol

View full text Add to dashboard Cite

EditorialIntravenous administration of interleukin-2 (IL-2) is a useful therapy for stage IV melanoma and renal cell cancer, stimulating proliferation of T cells, lymphocyte activated killer cells, natural killer cells and other immune effectors, which then target and eliminate cancer cells. In about 15 % of patients, tumor burden is significantly lessened and complete cure is seen in 6 -8 %. 1-3 However, IL-2 therapy can cause severe side effects including pulmonary edema, psychosis, renal failure, hepatitis and myocardial infarctions. 3 The treatment protocols basically simulate septic shock to get an immune response against cancer. Patients have to pass a cardiac stress test before starting IL-2, and as a result many patients are precluded from even starting IL-2 therapy. Those medically cleared for the grueling protocol undergo intensive care level monitoring while receiving IL-2 infusions. Even for patients able to tolerate IL-2 therapy without permanent harm, almost always the number of doses given in any cycle is well below the optimal amount because of patients start showing unacceptable side effects. I personally have had the experience of patients experiencing severe shaking rigors, at the very threshold of threatened end organ damage, yet desperately pleading for just one more dose of IL-2, to get just that much more chance of disease-free survival. Those desperate patients prompt me to propose to this audience that we should consider reviving the old idea of administering IL-2 into the splenic artery instead of the systemic circulation.The concept of splenic artery infusion of IL-2 for cancer immunotherapy goes back over a quarter of a century, but new efforts are needed. The basic premise, validated in data so far, is that you need far smaller amounts of intrasplenically infused IL-2 to get maximum immune response, and most, if not all, of the IL-2 has its action within the spleen rather than the systemic circulation. The spleen gives rise to 25 % of total circulating T lymphocytes and 10 -15 % of B lymphocytes, and about 50 % of all lymphocytes in the body are thought to pass through the splenic arterioles in the course of their lifetime. The spleen receives 100 % of its arterial blood supply from the splenic artery, making percutaneous access relatively easy. Pilot testing of splenic artery infusion of IL-2 first took place in mouse models in the mid 1980's. 4 Subsequently in 1990, 20 patients with stage IV renal cell cancer, melanoma and lymphoma underwent a phase I clinical trial with low dose IL-2 continuously infused over 5 consecutive days at 3 weeks intervals for 2 -4 cycles via a splenic arterial catheter placed through the femoral artery. 5 Each patient received from 90,000 -240,000 IU/kg/day for a total dose of 450,000-1.2 millionIU/kg/cycle, much lower than the maximum dose of 8.4 million IU/kg/cycle with current systemic IL-2. In 3 of the 20 patients, visible reduction of tumor burden could be demonstrated. Two patients with renal cell cancer had complete regression of hepatic metastase...

show abstract

mentioning

confidence: 99%

Splenic artery infusion of IL-2 might allow treatment of melanoma and renal cell cancer with less side effects and greater efficacy

Alisky¹

2014

Int J Cancer Ther Oncol

View full text Add to dashboard Cite

show abstract

Study of administration of rIL-2 with mixed micelles into large intestine.

勝浩¹,

豊²,

俊彦³

et al. 1993

DDS

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Continuous Intrasplenic Interleukin-2 Combined With Antigen-Specific Chemoimmunotherapy

Cited by 2 publications

References 26 publications

Splenic artery infusion of IL-2 might allow treatment of melanoma and renal cell cancer with less side effects and greater efficacy

Splenic artery infusion of IL-2 might allow treatment of melanoma and renal cell cancer with less side effects and greater efficacy

Study of administration of rIL-2 with mixed micelles into large intestine.

Contact Info

Product

Resources

About